News
Johnson & Johnson (NYSE:JNJ) submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia ...
Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced ...
The supplemental New Drug Application is supported by Phase III data, which showed Caplyta significantly prolonged time to ...
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...
Johnson & Johnson submits sNDA to US FDA for Caplyta for prevention of relapse in schizophrenia: Titusville, New Jersey Wednesday, July 9, 2025, 14:00 Hrs [IST] Johnson & Johnson ...
Titusville: Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...
2d
Stocktwits on MSNJohnson & Johnson Submits Supplemental Drug Application To FDA For Schizophrenia Drug CaplytaJohnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...
After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...
Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone.
J&J(JNJ) wins U.S. appeals court case protecting its Invega Sustenna patent from generic rivals Viatris (VTRS) & Teva (TEVA).
2don MSN
Scientists have discovered novel drug candidates which could ultimately lead to new effective treatments for conditions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results